| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Michelle R Salvaggio | Q124718987 |
| P2093 | author name string | Tauseef Ali | |
| Aftab Ahmed | |||
| Khadija Chaudrey | |||
| Sultan Mahmood | |||
| P2860 | cites work | Thymus-independent and thymus-dependent responses to polysaccharide antigens | Q28249349 |
| A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults | Q28278176 | ||
| FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) | Q28283721 | ||
| FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP) | Q28283731 | ||
| Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q28294460 | ||
| Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q33502869 | ||
| A practical guide to vaccinating the inflammatory bowel disease patient | Q33526774 | ||
| Abnormalities of uterine cervix in women with inflammatory bowel disease | Q33869002 | ||
| Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q34012075 | ||
| Vaccinations in patients with immune-mediated inflammatory diseases | Q34117134 | ||
| Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. | Q34158752 | ||
| Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines | Q34173362 | ||
| Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q34640567 | ||
| Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q34653033 | ||
| Human papillomavirus infection in HIV-infected persons. | Q34667587 | ||
| Guidelines for immunizations in patients with inflammatory bowel disease | Q35912322 | ||
| The epidemiology of genital human papillomavirus infection | Q36365671 | ||
| Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression. | Q36496958 | ||
| Diphtheria. | Q36600104 | ||
| Thoracic manifestations of inflammatory bowel disease | Q36734393 | ||
| Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease | Q36916512 | ||
| Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases | Q36932760 | ||
| Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample | Q36959801 | ||
| Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease | Q84984314 | ||
| Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab | Q85003398 | ||
| Pertussis | Q87016729 | ||
| Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014 | Q87497165 | ||
| Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q95432989 | ||
| Varicella vaccination of immunocompromised children | Q37141159 | ||
| Immune response to influenza vaccine in children with inflammatory bowel disease | Q37247576 | ||
| Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital | Q37267297 | ||
| Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease | Q37456737 | ||
| Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics | Q37492480 | ||
| General health maintenance in IBD. | Q37547079 | ||
| Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. | Q37579958 | ||
| Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. | Q37854550 | ||
| Varicella immunity in inflammatory bowel disease | Q37866970 | ||
| An upsurge in pertussis: epidemiology and trends | Q37985569 | ||
| Varicella zoster virus infection in inflammatory bowel disease | Q37995573 | ||
| Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease | Q40261410 | ||
| Adult immunization: principles and practice. | Q40825926 | ||
| Bloodstream infection caused by nontoxigenic Corynebacterium diphtheriae in an immunocompromised host in the United States | Q42196194 | ||
| Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. | Q42252569 | ||
| Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). | Q42270134 | ||
| Would CLSI M53-A have helped in the diagnosis of HIV in Canada? Results of the performance of Canadian laboratories participating in a recent NLHRS proficiency testing panel containing HIV-1 antigen positive (antibody negative) and HIV-2 samples | Q42281094 | ||
| Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease | Q42609131 | ||
| Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. | Q43171699 | ||
| Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. | Q43577164 | ||
| Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease | Q43758219 | ||
| Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease | Q44036752 | ||
| Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. | Q44235535 | ||
| Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. | Q44804708 | ||
| Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. | Q44831801 | ||
| Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine | Q45390667 | ||
| Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. | Q45844100 | ||
| Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older--United States, 2013. | Q45947805 | ||
| Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. | Q45956101 | ||
| Lack of association between cervical dysplasia and IBD: a large case-control study. | Q46763658 | ||
| A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. | Q50934590 | ||
| Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. | Q51378548 | ||
| H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. | Q51512458 | ||
| Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. | Q52128841 | ||
| Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study | Q58873378 | ||
| Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study | Q59509574 | ||
| Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease | Q59563630 | ||
| Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study* | Q62476169 | ||
| Crohn's disease, measles, and measles vaccination: a case-control failure | Q70874497 | ||
| Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) | Q73269527 | ||
| Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project | Q73570596 | ||
| Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003 | Q81216904 | ||
| Higher incidence of abnormal Pap smears in women with inflammatory bowel disease | Q81452560 | ||
| Digestive Disease Week and the 107th Annual Meeting of the American Gastroenterological Association Institute, May 20-25, 2006, Los Angeles, California, USA. Abstracts | Q83208821 | ||
| [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease] | Q83444905 | ||
| Pertussis epidemic--Washington, 2012 | Q84586403 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 3184-3196 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Updates in vaccination: recommendations for adult inflammatory bowel disease patients | |
| P478 | volume | 21 |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q40600058 | Guidelines for vaccination of immunocompromised individuals |
| Q64234383 | Improving immunization strategies in patients with inflammatory bowel disease |
| Q64882847 | OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines. |
| Q28078112 | Preventive health measures in inflammatory bowel disease |
| Q91706575 | Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease |
| Q89947372 | Uselessness of Serum p53 Antibody for Detecting Colitis-associated Cancer in the Era of Immunosuppressive Therapy |
| Q36696850 | Using Computerized Physician Order Entry to Ensure Appropriate Vaccination of Patients with Inflammatory Bowel Disease |
| Q28066325 | Vaccination of special populations: Protecting the vulnerable |
| Q90483468 | Vaccination status of patients using anti-TNF therapy and the physicians' behavior shaping the phenomenon: Mixed-methods approach |
Search more.